Nasal Hyperreactivity and Inflammation in Allergic Rhinitis

Mediators of Inflammation

Volumn 5, Issue 2, 1996, Pages 79-94

  Garrelds, I M ^a,b   Zijlstra, F J ^a   de Graaf in't Veld C ^b   Gerth van Wijk, R ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Allergy; nasal hyperreactivity; nasal inflammation; rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; DECONGESTIVE AGENT; EOSINOPHIL CATIONIC PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; IPRATROPIUM BROMIDE; LIPOXYGENASE; NITRIC OXIDE; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE; TERFENADINE; THROMBOCYTE ACTIVATING FACTOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC RHINITIS; ANTIGEN PRESENTING CELL; BLOOD VESSEL PERMEABILITY; HAY FEVER; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY CELL; NOSE MUCOSA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0029780064     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/S0962935196000142     Document Type: Article

References (238)

1. Blackley CH. Experimental Researches on the Cause and Nature of Catarrhus Aestivus (Hay Fever or Hay Asthma). London: Balliere, Tindall and Cox (reprinted 1959 by Dawson’s of Pall Mall), 1873; 77–134.
2. Von Pirquet C. Allergie. Munch Med Wochenschr 1906; 53: 1457–1458.
3. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. J Immunol 1923; 8: 163.
4. Prausnitz C, Küstner H. Studien über überempfindlichkeit. Centralbl Bakteriol 1921; 86: 160.
5. Ishizaka K, Ishizaka T, Hornbrook MM. Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966; 97: 75–85.
6. Johansson SGO, Bennich H. Immunological studies of an atypical immunoglobulin. Immunology 1967; 13: 381–394.
7. Gell PGH, Coombs RRA. Clinical Aspects of Immunology. 2nd ed. Oxford: Blackwell Scientific Publications, 1968; 575–596.
8. Voorhorst R. Basic Facts of Allergy. Leiden: Stenfert Kroese, 1962; 5–12.
9. Middleton E Jr, Reed CE, Ellis EF (eds). Allergy, Principles and Practice. 2nd ed. St Louis: Mosby 1983: XXI–XXII.
10. Evans R, III. Epidemiology and natural history of asthma, allergic rhinitis and atopic dermatitis. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, eds. Allergy: Principles and Practice. Vol. II. St. Louis: C.V. Mosby, 1993: 1109–1136.
11. Åberg N, Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989; 19: 59–63.
12. Barbee R, Kaltenborn W, Lebowitz W, Burrows B. Longitudinal changes in allergic skin test reactivity in a community population sample. J Allergy Clin Immunol 1987; 79: 16–24.
13. International rhinitis management working group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49 (suppl): 1–34.
14. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77–83.
15. Connell JT. Quantitative intranasal pollen challenge. I. Apparatus design and technique. J Allergy 1966; 39: 358.
16. Greiff L, Pipkorn U, Alkner U, Persson CG. The “nasal pool” device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy 1990; 20: 253–259.
17. Naclerio RM, Meier HL, Hagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. J Allergy Clin Immunol 1983; 128: 597–602.
18. Clement PAR. Committee report on standardization of rhinomanometry. Rhinology 1984; 22: 151–155.
19. Wihl JA, Malm L. Rhinomanometry and nasal peak expiratory and inspiratory flow rate. Ann Allergy 1988; 61: 50–55.
20. Fisher EW, Lund VJ, Scadding GK. Acoustic rhinometry in rhinological practice: discussion paper. J Royal Society Med 1994; 87, 411–413.
21. Hallén H, Juto HE. Nasal mucosa reaction. A model form ucosal reaction during challenge. Rhinology 1992; 30: 129–133.
22. Borum P, Mygind N. Inhibition of the immediate allergic reaction in the nose by the β2 adrenostimulant fenoterol. J Allergy Clin Immunol 1980; 66: 25–32.
23. Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988; 82: 869–877.
24. Varney VA, Jacobson MR, Sudderick RM, et al. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Am Rev Respir Dis 1992; 146: 170–176.
25. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticoids. N Engl J Med 1987; 316: 1506–1510.
26. Meltzer EO. Evaluating rhinitis: clinical, rhinomanometric and cytologic assessments. J Allergy Clin Immunol 1988; 82: 900–908.
27. Gomez E, Corrado OJ, Baldwin DL, Swanston AR, Davies RJ. Direct evidence for mast cell degranulation during allergen-induced reactions in man. J Allergy Clin Immunol 1986; 78: 637–645.
28. Fokkens WJ, Godthelp T, Holm AF, Blom H, Mulder PGH, Vroom TM, Rijntjes E. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: a biopsy study. Clin Exp Allergy 1992; 22: 701–710.
29. Pelikan Z. Late and delayed responses of the nasal mucosa to allergen challenge. Ann Allergy 1978; 41: 37–46.
30. Mygind N, Grønborg H, Bisgaard H, Romeling F. Nasal late-phase response to allergen provocation: does it exist? In: New Developments in Mechanisms and Treatment of Bronchial Obstruction. Dijkman JH, van Herwaarden CLA, Hilvering Chr, Kerrebijn KF, eds. Astra Pharmaceutica 1988; 41–50.
31. Fergusson H, Davies RJ. Late phase nasal reactions—reviewed and revisited. Respir Med 1991; 85: 247–249.
32. De Graaf-In’t Veld C, Garrelds IM, Jansen APH, van Toorenenbergen AW, Mulder PGH, Meeuwis J, Gerth van Wijk R. Effect of fluticasone propionate on the immediate and late allergic nasal reaction and nasal hyperreactivity in patients with a house dust mite allergy. Clin Exp Allergy 1995; 25: 966–973.
33. Connell JT. Quantitative intranasal pollen challenge. III. The priming effect in allergic rhinitis, J Allergy 1969; 43: 33–44.
34. Bacon JR, McLean JA, Mathews KP, Banas JM. Priming of the nasal mucosa by ragweed extract or by an irritant (ammonia). J Allergy Clin Immunol 1981; 67: 111–116.
35. Gerth van Wijk R, Dieges PH, van Toorenenbergen AW. Seasonal variability in nasal sensitivity to house dust mite extract. Rhinology 1987; 25: 41–48.
36. McLean JA, Mathews KP, Solomon WR, Brayton PR, Ciarkowski AA. Effect of histamine and methacholine on nasal airway resistance in atopic and nonatopic subjects. J Allergy Clin Immunol 1977; 59: 65–70.
37. Gerth van Wijk R, Mulder PGH, Dieges PH. Nasal provocation with histamine in allergic rhinitis patients: clinical significance and reproducibility. Clin Exp Allergy 1989; 19: 293–298.
38. Gerth van Wijk R, Dieges PH. A comparison of nasal responsiveness to histamine, methacholine and phentolamine in allergic rhinitis patients and controls. Clin Allergy 1987; 17: 563–570.
39. Borum P, Grønborg H, Brofeldt S, Mygind N. Nasal reactivity in rhinitis. Eur J Respir Dis 1983; 64(suppl): 65–71.
40. Klementsson H, Andersson M, Baumgarten CR, Venge P, Pipkorn U. Changes in nonspecific nasal reactivity and eosinophil influx and activation after allergen challenge. Clin Exp Allergy 1990; 20: 539–549.
41. Konno A, Yamakoshi T, Terada N, Fujita Y. Mode of action of a topical steroid on immediate phase reaction after antigen challenge and nonspecific nasal hyperreactivity in nasal allergy. Int Arch Allergy Immunol 1994; 103: 79–87.
42. In’t Veld C, Garrelds IM. Nasal hyperreactivity and inflammation in perennial allergic rhinitis. Thesis 1995, Rotterdam, The Netherlands.
43. Buckle FG, Cohen AB. Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrinsic asthma. J Allergy Clin Immunol 1975; 55: 213–212.
44. Megen van YJB, Klaassen ABM, Rodrigues de Miranda JF, Ginneken van CAM, Wentges RTR. Alterations of muscarinic acetylcholine receptors in the nasal mucosa of allergic patients in comparison with non-allergic individuals. J Allergy Clin Immunol 1991; 87: 521–529.
45. Barnes ST. Asthma as an axon reflex. Lancet 1986; 1: 242–245.
46. Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in non-allergic bronchial reactivity. Clin Allergy 1977; 7: 503–513.
47. Cartier A, Thomson NC, Frith PA, Roberts R, Tech M, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982; 70: 170–177.
48. Gerth van Wijk R, Zijlstra FJ, van Toorenenbergen AW, Vermeulen A, Dieges PH. Isolated early response after nasal allergen challenge is sufficient to induce nasal hyperreactivity. Ann Allergy 1992; 69: 43–47.
49. Iliopoulos O, Proud D, Adkinson NF, et al. Effect of immunotherapy on the early, late and rechallenge nasal reaction to provocation with allergen-changes in inflammatory mediators and cells. J Allergy Clin Immunol 1991; 87: 855–866.
50. Gerth van Wijk R, van Toorenenbergen AW, Zijlstra RJ, Jansen APH, Dieges PH. Nasal hyperreactivity and its effects on early and late sequelae of nasal challenge with house dust mite extract. Allergy Proc 1993: 14: 273–281.
51. Schwartz LB, Irani AA, Roller K, Castells MC, Schechter NM. Quantitation of histamine, tryptase and chymase in dispersed human T and TC mast cells. J Immunol 1987; 138: 2611–2615.
52. Schleimer RP, MacGlashan Jr DW, Peters SP, Pinckard RN, Adkinson Jr NF, Lichtenstein LM. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Respir Dis 1986; 133: 614–617.
53. Freeland HS, Schleimer RP, Schulman ES, Lichtenstein LM, Peters SP. Generation of leukotriene B4 by human lung fragments and purified human lung mast cells. Am Rev Respir Dis 1988; 138: 389–394.
54. Braquet P, Touqui, L, Shen TY, Vargaftig BB. Perspectives in plateletactivating factor research. Pharmacol Rev 1987; 39: 97–145.
55. Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and TNF-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10: 471–480.
56. Wodnar-Filipowicz A, Heusser CH, Moroni C. Production of the hematopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 1989; 339: 150–152.
57. Wasserman SI. Mast cells and airway inflammation in asthma. Am J Respir Crit Care Med 1994; 150: S39–S41.
58. Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. Purification and characterisation. J Biol Chem 1981; 256: 11939–11943.
59. Schwartz LB, Bradford TR, Irani AA, Deblois G, Craig SS. The major enzymes of human mast cell secretory granules. Am Rev Respir Dis 1987; 135: 1186–1189.
60. Bacci S, Arbi-Riccardi R, Mayer B, Rumio C, Borghi-Cirri MB. Localization of nitric oxide synthase immunoreactivity in mast cells of human nasal mucosa. Histochemistry 1994; 102: 89–92.
61. Togais AG, Naclerio RM, Proud D, Fish JE, Adkinson NF, Kagey-Sobotka A. Nasal challenge with cold dry air results in release of inflammatory mediators—possible mast cell involvement. J Clin Invest 1985; 62: 574–581.
62. Enerbäck L, Granerrus G, Pipkorn U. Intraepithelial migration of mast cells in hay fever. Int Archs Allergy Appl Immunol 1986; 80: 44–54.
63. Viegas M, Gomez E, Brooks J, Davies RJ. Changes in mast cell number in and out of the pollen season. Int Arch Allergy Appl Immunol 1987; 82: 275–276.
64. Borres MP, Irander K, Bjorksten B. Metachromatic cells in nasal mucosa after allergen challenge. Allergy 1990; 45: 98–103.
65. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328: 257–265.
66. 1(T6), HLA-DR expressing cells, presumable Langerhans cells, in the nasal mucosa of patients with an isolated grass-pollen allergy before, during and after the grass pollen season. J Allergy Clin Immunol 1989; 84: 39–43.
67. Juliusson S, Bachert C, Klementsson H, Karlsson G, Pipkorn U. Macrophages on the nasal mucosal surface in provoked and naturally occurring allergic rhinitis. Acta Otolaryngol (Stockh) 1991; 11: 946–953.
68. Joseph M, Tonnel AB, Torpier G, Capron J, Arnoux B, Benveniste J. Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J Clin Invest 1983; 71: 221–230.
69. 4 and prostanoids by human alveolar macrophages: analysis by gas chromatography/mass spectrometry. Prostaglandins 1984; 27: 163–179.
70. 2 from human monocytes stimulated with aggregated IgG, IgA, and IgE. J Immunol 1986; 36: 4188–4193.
71. Goldstein IM, Malmsten CL, Kindahl H, Kaplan HB, Radmark O, Samuelsson B, Weissmann G. Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med 1978; 148: 787–792.
72. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991; 88: 561–571.
73. Siracusa A, Vecchiarelli A, Brugnami G, Marabini A, Felicioni D, Severini C. Changes in interleukin-1 and tumor necrosis factor production by peripheral blood monocytes after specific bronchoprovocation test in occupational asthma. Am Rev Respir Dis 1992; 146: 408–412.
74. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic airways. J Allergy Clin Immunol 1992; 89: 958–967.
75. Malefyt RDW, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–1220.
76. Joseph M, Tonnel AB, Capron A, Voisin C. Enzyme release and superoxide anion production by human alveolar macrophages stimulated with immunoglobulin E. Clin Exp Immunol 1980; 40: 416–422.
77. Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Resp Cell Mol Biol 1993; 9: 371–377.
78. Holt PG, Schon-Hegrad MA, Oliver J. MHC class II antigen-bearing dendritic cells in pulmonary tissues in the rat: regulation of antigen presentation activity by endogenous macrophage population. J Exp Med 1988; 167: 262–274.
79. Hunter JA, Finkbeiner WE, Nadel JA, Goetzl EJ, Holtzman MJ. Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. Proc Natl Acad Sci USA 1985; 82: 4633–4637.
80. 2 release by canine tracheal epithelium. Am J Physiol 1985; 248: 48–55.
81. Widdicombe JH, Ueki IF, Emery DL, Margolskee D, Yergey J, Nadel J. Release of cyclooxygenase products from primary cultures of tracheal epithalia of dog and human. Am J Physiol 1989; 257: L361–L365.
82. Salari H, Wong A. Generation of platelet activating factor (PAF) by a human lung epithelial cell line. Eur J Immunol 1990; 175: 253–259.
83. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Tarraf H, Davies RJ. Effect of Haemophilus influenza endotoxin on the synthesis of IL-6, IL-8, TNF-α and expression of ICAM-1 in cultured human bronchial epithelial cells. Eur Respir J 1994; 7: 2109–2116.
84. Churchill L, Friedman B, Schleimer RP, Proud D. Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells. Immunology 1992; 75: 189–195.
85. Marasco WA, Showell HJ, Becker EL. Substance P binds to the formylpeptide chemotaxis receptor on the rabbit neutrophil. Biochem Biophys Res Comm 1981; 99: 1065–1072.
86. Asano K, Chee CB, Gaston B, et al. Constitutive and inducible nitric oxide synthase gene expression, regulation and activity in human lung epithelial cells. Proc Natl Acad Sci USA 1994; 91: 10089–10093.
87. Ruff MR, Wahl SM, Pert CB. Substance P receptor mediated chemotaxis of human monocytes. Peptides 1985; 6: 107–111.
88. Bar-Shavit Z, Goldman R, Stubinsky Y, et al. Enhancement of phagocytosis—a newly found activity of substance P residing in its N-terminal tetrapeptide sequence. Biochem Biophys Res Comm 1990; 4: 1445–1451.
89. Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T-lymphocytes by substance P. J Immunol 1983; 131: 1613–1615.
90. Foreman JC, Jordan CC. Histamine release in vascular changes induced by neuropeptides. Agents Actions 1983; 13: 105–116.
91. Al-Bazzaz FJ, Kelsey JG, Kaage WD. Substance P stimulation of chloride secretion by canine tracheal mucosa. Am Rev Respir Dis 1985; 131: 86–89.
92. Tanaka DT, Grunstein MM. Mechanisms of substance P-induced contraction of rabbit airway smooth muscle. J Appl Physiol 1984; 57: 1551–1557.
93. 4-macromolecules from ferret trachea. Exp lung Res 1987; 12: 21–36.
94. Cox G, Ohtoshi T, Vancheri C, Denburg JA, Dolovich J, Gauldie J, Jordana M. Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids. Am J Respir Cell Mol Biol 1991; 4: 525–531.
95. Chavance M, Herbeth B, Kauffmann F. Seasonal patterns of circulating basophils. Int Arch Allergy Appl Immunol 1988; 86: 462–464.
96. Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ, Lichtenstein LM. Basophil influx occurs after nasal antigen challenge; effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 1988; 81: 580–589.
97. Alam R, Grant JA. Basophils: biology and function in airway disease. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Cambridge, MA: Blackwell Scientific Publications. 1995; 20: 242–251.
98. Bischoff SC, Brunner T, de Week AL, Dahinden CA. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med 1990; 172: 1577–1582.
99. Triggiani M, Schleimer RP, Warner JA, Chilton FH. Differential synthesis of 1-acyl-2-acetyl-5n-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J Immunol 1991; 147: 660–666.
100. Steffen M, Abboud M, Potter GK, Yung YP, Moore MA. Presence of tumor necrosis factor or related factor in human basophil/mast cells. Immunology 1989; 66: 445–450.
101. Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987; 1381: 2184–2189.
102. Wasserman SI, Goetzl EJ, Austen KF. Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulphatase. J Immunol 1975; 114: 645–649.
103. Zeiger RS, Yurdin DL, Colten HR. Histamine metabolism. II. Cellular and subcellular localization of the catabolic enzymes, histaminase and histamine methyl transferase, in human leukocytes. J Allergy Clin Immunol 1976; 58: 172–179.
104. Altman LC, Ayars GH, Baker C, Luchtel DL. Cytokines and eosinophil-derived cationic proteins up regulate ICAM-1 on human nasal epithelial cells. J Allergy Clin Immunol 1993; 92: 527–536.
105. Owen Jr WF, Soberman RJ, Yoshimoto T, Sheffer AL, Lewis RA, Austen KF. Synthesis and release of leukotriene C4 by human eosinophils. J Immunol 1987; 138: 532–538.
106. Kroegel C, Matthys H. Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclooxygenase metabolites in human blood eosinophils from asthmatics. Immunology 1993; 78: 279–285.
107. Turk J, Maas RL, Brash AR, Roberts LJ, Oates JA. Arachidonic acid 15-lipoxygenase products from human eosinophils. J Biol Chem 1982; 257: 7068–7076.
108. Kita H, Ohnish T, Okubo Y, Weiler D, Adams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin-3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991; 174: 745–748.
109. Desreumaux P, Janin A, Colombel JF, et al. Interleukin-5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 1992; 175: 293–296.
110. Hamid Q, Barkans J, Meng Q, et al. Human eosinophils synthesize interleukin-6 in vitro. Blood 1992; 80: 1496–1501.
111. Costa JJ, Matossian K, Resnick MB, et al. Human eosinophils can express the cytokines tumor necrosis factor-α and macrophages inflammatory protein-1α. J Clin Invest 1993; 91: 2673–2684.
112. Hamann KJ, Barker RL, Ten RM, Gleich GJ. The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol 1991; 94: 202–209.
113. McCormick ML, Roeder TL, Railsback MA, Britigan BE. Eosinophil peroxidase-dependent hydroxyl radical generation by human eosinophils. J Biol Chem 1994; 269: 27914–27919.
114. Gleich GJ, Flavahan NA, Fujisawa T, Vanhuette PM. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988; 81: 776–781.
115. Hamann KJ, White SR, Gundel RH, Gleich GJ. Interactions between respiratory epithelium and eosinophil granule proteins in asthma: the eosinophil hypothesis. In: Farmer SG, Hay DWP, eds. The Airway Epithelium: Structure and Function in Health and Disease. New York: Marcel Dekker, 1991; 255–300.
116. Eyerman C. Nasal manifestations of allergy. Ann Otol Rhinol Laryngol 1927; 36: 539–547.
117. Lindsay JR, Walsh TE. Nasal secretions—the value of cytologic examination of the rhinologist. Arch Otol 1933; 1: 783–786.
118. Rand TH, Cruikshank WW, Center D, Weller P. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 1991; 173: 1521–1528.
119. Bascom R, Pipkorn U, Lichteinstein LM, Naclerio RM. The influx of inflammatory cells into nasal washings during the late response to allergen challenge. Am Rev Respir Dis 1988; 138: 406–412.
120. Pelikan Z. The changes in the nasal secretions of eosinophils during the immediate nasal response to allergen challenge. J Allergy Clin Immunol 1983; 72: 657–662.
121. Hogg JC. Neutrophil kinetics and lung injury. Physiol Rev 1987; 67: 1249–1295.
122. Harlan JM. Consequences of leukocyte-vessel wall interactions in inflammatory and immune reactions. Semin Thromb Hemost 1987; 13: 434–444.
123. Venge P, Hakansson L, Rak S, Dahl R, Fredens K. Inflammatory cells in Asthma and rhinitis. In: Mygind N, Pipkorn U, Dahl R, eds. Rhinitis and Asthma: similarities and differences. Copenhagen: Munksgaard, 1990; 188–202.
124. Cassatella MA, Bazzoni F, Ceska M, Ferro K, Baggiolini M, Berton G. IL-8 production by human polymorphonuclear leukocytes: the chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression and release of IL-8 through a pertussis toxin-sensitive pathway. J Immunol 1992; 148: 3216–3220.
125. Sedgwick JB, Vrtis RF, Gousley MF, Busse WW. Stimulus-dependent difference in superoxide anion generation by normal human eosinophils and neutrophils. J Allergy Clin Immunol 1988; 81: 876–883.
126. Albegger K. Current pathophysiologic aspects of allergic rhinitis. Hals-Nasen-Ohren 1990; 38: 305–308.
127. Graham D, Henderson F, House D. Neutrophil influx measured in nasal lavages of humans exposed to ozone. Arch Environ Health 1988; 43: 228–233.
128. Gourdin MF, Vasconcelos AW, Tabilio A, Divine M, Fazcet FP, Reyes F. Human mononuclear phagocyte differentiation: a study of the U-937 cell line by ultrastructural cytochemistry and surface antigen analysis. Br J Haematol 1985; 61: 281–289.
129. Takatsu K, Tominaga A, Harada N, et al. T cell-replacing factor (TRF)/interleukin-5 (IL-5): molecular and functional properties. Immunol Rev 1988: 102: 107–135.
130. Mossmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T-cell clones. J Immunol 1986; 136: 2348–2357.
131. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and function of helper T cells. Adv Immunol 1989; 46: 111–147.
132. Kapsenberg ML, Jansen HM, Bos JD, Wierenga EA. Role of type 1 and type 2 T helper cells in allergic diseases. Curr Opin Immunol 1992; 4: 788–793.
133. Gonzalez C, Diaz P, Galleguillos F, Ancic P, Cromwell O, Kay AB. Allergen-induced recruitment of bronchoalveolar T-helper (OKT4) and T-suppressor (OKT8) cells in asthma. Relative increases in OKT8 cells in single early responders compared with those in late-phase responders. Am Rev Respir Dis 1987; 136: 600–604.
134. Frew AJ, Kay AB. The relationship between infiltrating CD4+ lymphocytes, activated eosinophils and the magnitude of the allergen-induced late phase cutaneous reaction. J Immunol 1988; 141: 158–164.
135. Jacobson MR, Varney VA, Sudderick R, Robinson DS, Mackay IS, Kay AB, Durham SR. Immunohistology of allergen-induced late nasal responses. J Allergy Clin Immunol 1991; 87: 304.
136. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and other bronchial provocation. Am Rev Respir Dis 1989; 140: 806–817.
137. Knauer KA, Lichtenstein LM, Adkinson Jr NF, Fish JE. Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Engl J Med 1981; 304: 1404–1407.
138. Audera C, Rocklin R, Vaillancourt R, Jakubowski A, Deykin D. Altered arachidonic acid metabolism and platelet size in atopic subjects. Clin Immunol Immunopathol 1988; 46: 352–359.
139. Day RP, Behmann S, Dolovich J, Hargreave FE. Inflammatory effects of leukocytes and platelets. J Allergy Clin Immunol 1975; 55: 87–93.
140. Mustard JF, Kinlough-Rathbone RL, Packham MA. Platelet activation—an overview. In: Schmitz-Schumann M, Menz G, Page CP, eds. PAF, Platelets and Asthma. Basel: Birkhauser-Verlag, 1987; 23–26.
141. Turner SR, Tainer JA, Lynn WS. Biogenesis of chemotactic molecules by the arachidonic lipoxygenase system of platelets. Nature 1975; 257: 680–683.
142. 2 by human platelets. Prostaglandins 1977; 13: 225–234.
143. Finazzi-Agro A, Menichelli A, Persiani M, Biancini G, Del Principe D. Hydrogen peroxide release from human blood platelets. Biochim Biophys Acta 1982; 718: 21–25.
144. Fisher RH, Metzger WJ, Mediator functions of platelets. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Cambridge, MA: Blackwell Scientific Publications, 1995; 39: 513–529.
145. Kaplan A, Beaven M. In vivo studies of the pathogenesis of cold urticaria, cholinergic urticaria and vibration-induced swelling. J Invest Dermatol 1976; 67: 327–332.
146. Dale H, Laidlaw P. The physiologic action of β-imidazoliethylamine. J Physiol (Lond) 1911; 41: 318–344.
147. Ash, A, Schild H. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427–439.
148. Curry J. The action of histamine on the respiratory tract in normal and asthmatic subjects. J Clin Invest 1946; 25: 785–791.
149. Becker C, Nachman R. Contractile proteins of endothelial cells, platelets and smooth muscle. Am J Pathol 1973; 71: 1–22.
150. 2-receptors. Nature 1972; 236: 385–390.
151. Marin M, Davis B, Nadel J. Effect of histamine on electrical and ion transport properties of tracheal epithelium. J Appl Physiol 1977; 42: 735–738.
152. Clark R, Gallin J, Kaplan A. The selective eosinophil chemotactic activity of histamine. J Exp Med 1975; 142: 1462–1476.
153. Seligmann BE, Fletcher MP, Gallin JI. Histamine modulation of human neutrophil oxidase metabolism, locomotion, degranulation, and membrane potential changes. J Immunol 1983; 130: 1902–1909.
154. 2 antihistamines augment antigen-induced histamine release from human basophils in vitro. J Immunol 1982; 129: 2113–2115.
155. Fallah H, Maillard J, Voison G. Regulatory mast cells. I. Suppressive actions of their prodcuts on an in vitro primary immunoreaction. Ann Immunol (Paris) 1975; 126: 669–682.
156. Melmon K, Bourne H, Weinstein Y, Shearer G, Kram J, Bauminger S. Hemolytic plaque formation by leukocytes in vitro. J Clin Invest 1974; 53: 13–21.
157. Lima M, Rocklin R. Histamine modulates in vitro IgG production by pokeweed mitogen-stimulated human mononuclear cells. Cell Immunol 1981; 64: 324–336.
158. Corrado O, Gould C, Kassab J, Davies R. Nasal response of rhinitic and non-rhinitic subjects to histamine and methacholine: a comparative study. Thorax 1986; 41: 863–868.
159. Walls AF. The role of neutral proteases in asthma and rhinitis. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Cambridge, MA: Blackwell Scientific Publications, 1995; 62.
160. Caughey GH. The structure and airway biology of mast cell proteinase. Am J Respir Cell Mol Biol 1991; 4, 387–394.
161. Proud D, Bailey GS, Naclerio RM, et al. Tryptase and histamine as markers to evaluate mast cell activation during the response to nasal challenge with allergen, cold dry air, and hyperosmolar solutions. J Allergy Clin Immunol 1992; 89: 1098–1110.
162. 2α on human isolated bronchus. Prostaglandins 1986; 32: 25–31.
163. Spannhake EW, Hyman AL, Kadowitz PJ. Bronchoactive metabolites of arachidonic acid and their role in airway function. Prostaglandins 1981; 22: 1013–1026.
164. 2. Adv Prostag Thrombox Leukotr Res 1987; 17: 1067–1072.
165. Vane JR, Mitchell JA, Appletonn I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046–2050.
166. Samuelsson B, Goldyne M, Granström, Hamberg M, Hammarström S, Malmsten C. Prostaglandins and thromboxanes. In: Snell EE, Boyer PD, Meister A, Richardson CC, eds. Annual Review of Biochemistry. California: Annual reviews inc. 1978; 47: 997–1029.
167. Hardy CC, Bradding P, Robinson C, Holgate ST. Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma. J Appl Physiol 1988; 64: 1567–1574.
168. Coleridge HM, Coleridge JCG, Ginzel KH, Baker DG, Banzett RB, Morrison MA. Stimulation of “irritant” receptors and afferent C-fibres in the lungs by prostaglandins. Nature 1976; 264: 451–453.
169. O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygen-ase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–160.
170. Wenzel SE, Westcott JY, Smith HR, Larsen GL. Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups: an alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am Rev Respir Dis 1989; 139: 450–457.
171. Walters EH, Parrish RW, Bevan C, Smith AP. Induction of bronchial hypersensitivity: evidence for a role prostaglandins. Thoax 1981; 36; 571–574.
172. Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313: 65–70.
173. Garrelds IM, de Graaf-In’t Veld C, Jansen APH, Gerth van Wijk R, Zijlstra FJ. Effect of fluticasone propionate aqueous nasal spray treatment on platelet activating factor and eicosanoid production by nasal mucosa in patients with a house dust mite allergy. Mediators of Inflammation 1994; 3: 381–385.
174. Georgitis JW, Stone WD, Gottschlich G. Nasal inflammatory mediator release in ragweed allergic rhinitis: correlation with cellular influx into nasal secretions. Int Arch Allergy Appl Immunol 1991; 96: 231–237.
175. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171–1176.
176. 4, a potent chemokinetic and aggregating substance released from polymorphonuclear leucocytes. Nature 1981; 286: 264–265.
177. 4 and its omega-oxidized metabolites. FEBS Lett 1981; 136: 141–144.
178. Serhan CN, Hamberg M, Samuelsson B. Lipoxins, a novel series of compounds formed from arachidonic acid in human leucocytes. Proc Natl Acad Sci USA 1984; 81: 5335–5339.
179. Copas JL, Borgeat P, Gardiner PJ. The actions of 5, 12 and 15-HETE on tracheobronchial smooth muscle. Prostaglandins Leukotrienes Med 1982; 8: 105–114.
180. Goetzl EJ, Pickett WC. The human PMN leucocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs). J Immunol 1980; 125: 1789–1791.
181. Stenson WF, Parker CW. Monohydroxyeicotetraenoic acids (HETEs) induce degranulation of human neutrophils. J Immunol 1980; 124: 2100–2104.
182. 4 formation and luminol dependent chemiluminescence of human eosinophils. Pharm Res Commun 1986; 18: 61–69.
183. Lellouch-Tubiana A, Lefort J, Pirotzky E, Vargaftig BB, Pfister A. Ultra-structural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br J Exp Pathol 1985; 66: 345–355.
184. Yasaka T, Boxer LA, Baehner RL. Monocyte-aggregation and superoxideanion response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). J Immunol 1982; 128: 1939–1944.
185. Goswami SK, Ohashi M, Stathas P, Matrom ZV. Platelet-activating factor stimulates secretion of respiratory glycoconjugate from human airways in culture. J Allergy Clin Immunol 1989; 84: 726–734.
186. Welsh MJ, Widdicombe JH, Nadel JA. Fluid transport across the canine tracheal epithelium. J Appl Physiol 1980; 49: 905–909.
187. Columbo M, Casolaro V, Warner JA, MacGlashan Jr DW, Kagey-Sobotka A, Lichtenstein LM. The mechanism of mediator release from human basophils induces by platelet-activating factor. J Immunol 1990; 145: 3855–3861.
188. Vergaftig BB, Lefort J, Chignard C, Benveniste J. Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 1980; 65: 185–192.
189. Vargaftig BB, Lefort J, Rotilio D. Route-dependent interactions between PAF-acether and guinea-pig bronchopulmonary smooth muscle: relevance of cyclooxygenase mechanisms. In: Benveniste J, Arnoux B, eds. INSERM Symposium: Platelet Activating Factor and Structurally Related Lipids. Amsterdam: Elsevier Science Publishers, 1983; 23: 307–317.
190. Mazzoni L, Morley J, Page CP, Sanjar S. Induction of airway hyperresponsiveness by platelet activating factor in the guinea-pig. J Physiol 1985; 369: 107–114.
191. Cuss FM, Dixon CMS, Barnes PJ. Effect of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet 1986; II: 189–192.
192. Lai CKW, Jenkins JR, Polosa R, Holgate ST. Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects. J Appl Physiol 1990; 68: 919–926.
193. Gebre-Michael I, Leuenberger PH. Inhalation of 400 μg of platelet activating factor (PAF) does not induce bronchial hyperreactivity (BHR) as determined by spirometric tests. Eur Respir J 1989; 2: 302.
194. 2 into nasal fluids after allergenic challenge: possible role of the regulation of PAF release. J Allergy Clin Immunol 1994; 94: 109–119.
195. Andersson M, Pipkorn U. The effect of PAF on nasal hypersensitivity. Eur J Clin Pharmacol 1988; 35: 231–235.
196. Leggieri E, Tedeschi A, Lorini M, Bianco A, Miadonna A. Study of the effects of PAF-acether on human nasal airways. Allergy 1991; 46: 466–471.
197. Klementsson H, Andersson M. Eosinophil chemotactic activity of topical PAF on the human nasal mucosa. Eur J Clin Pharmacol 1992; 42: 295–299.
198. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986; 77: 527–537.
199. Henderson WR, Chi EY, Klebanoff SJ. Eosinophil peroxidase-induced mast cell secretion. J Exp Med 1980; 152: 265–279.
200. 4. J Immunol 1982; 128: 2609–2612.
201. Peterson CGB, Skoog V, Venge P. Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology 1986; 171: 1–13.
202. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea-pig tracheal epithelium in vitro. Am Rev Respir Dis 1989; 139: 801–805.
203. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991; 87: 1470–1473.
204. Venge P, Dahl R, Peterson CGB. Eosinophil granule proteins in serum after allergen challenge of asthmatic patients and the effects of anti-asthmatic medication. Int Arch Allergy Appl Immunol 1988; 87: 306–312.
205. Sedgwick JB, Calhoun WJ, Gleich GJ, et al. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Am Rev Respir Dis 1991; 144: 1274–1281.
206. Garrelds IM, de Graaf-In’t Veld C, Nahori M-A, Vargaftig BB, Gerth van Wijk R, Zijlstra FJ. Interleukin-5 and eosinophil cationic protein in nasal lavages of rhinitis patients. Eur J Pharmacol 1995; 275: 295–300.
207. Svensson C, Andersson M, Alkner U, Venge P, Persson CGA, Pipkorn U. Albumin bradykinins and eosinophil cationic protein on the nasal mucosal surface in patients with hay fever during natural allergen exposure. J Allergy Clin Immunol 1990; 85: 828–833.
208. Klementsson H, Svensson C, Andersson M, Venge P, Pipkorn U, Persson CGA. Eosinophils, secretory responsiveness and glucocorticoid-induced effects on the allergic nasal mucosa during a weak pollen season. Clin Exp Allergy 1991; 21: 705–710.
209. Haak-Frendscho M, Arai N, Arai K, Baeze ML, Finn A, Kaplan AP. Human recombinant granulocyte-macrophage-colony-stimulated factor and interleukin 3 cause basophil histamine release. J Clin Invest 1988; 82: 17–20.
210. Morita Y, Goto M, Miyamoto T. Effect of interleukin 2 on basophil histamine release. Allergy 1987; 42: 104–108.
211. Warner JA, Pienkowski MM, Plaut M, Norman PS, Lichtenstein LM. Identification of a histamine-releasing factor(s) in the late phase of cutaneous IgE-mediated reactions. J Immunol 1986; 136: 2583–2587.
212. Bischoff SC, de Week AL, Dahinden CA. Interleukin 3 granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA 1990; 87: 6813–6817.
213. Schleimer RP, Derse CP, Friedman B, et al. Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. J Immunol 1989; 143: 1310–1317.
214. Terada N, Konno A, Fukuda S, et al. IL-5 upregulates ICAM-1 gene expression in the nasal mucosa in nasal allergy, but not in non-allergic rhinitis. Int Arch Allergy Immunol 1995; 106: 139–145.
215. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87: 1541–1546.
216. Durham SR, Ying S, Varney VA, et al. Cytokine messenger RNA expression for IL-3, IL-4, IL-5 and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relation to tissue eosinophilia. J Immunol 1992; 148: 2390–2394.
217. Alam R, Sim TC, Hilsmeier K, Grant JA. Development of a new technique for recovery of cytokines from inflammatory sites in situ. J Immunol Methods 1992; 155: 25–29.
218. Fujisawa T, Abu-Ghazaleh RI, Kita H, Sanderdon CJ, Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J. Immunol 1990; 144: 642–646.
219. Sonoda Y, Arai N, Ogawa M. Humerol regulation of eosinophilpoiesis in vitro, analysis of the targets of interleukin-3, granulocyte/macrophage colony stimulating factor (GM-CSF) and interleukin-5. Leukemia 1989; 3: 14–18.
220. Rothenberg ME, Petersen J, Stevens RL, et al. IL-5-dependent conversion of normodense eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143: 2311–2316.
221. Gleich GJ, Adolphson CR. The eosinophil leukocyte: structure and function. Adv Immunol 1986; 39: 177–253.
222. Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K, Sanderson CJ, Kay AB. IL-5 increases the in vitro adhesion of human eosinophils but not neutrophils, in a leukocyte integrin (CDII/18)-dependent manner. Immunology 1990; 71: 258–265.
223. Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989; 19: 701–705.
224. Warringa RAJ, Mengelers HJJ, Kuijper PHM, et al. In vivo priming of platelet activating factor-induced eosinophil chemotaxis in allergic individuals. Blood 1992; 79, 1836–1841.
225. Björnsdottir US, Quan SF, Busse WW. Eosinophils and asthma. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Cambridge, MA: Blackwell Scientific Publications, 1995; 25: 328–346.
226. Corrigan CJ, Haczku A. Engesaeth V, et al. CD4 T lymphocyte activation in asthma is accompanied by increased serum concentrations of IL-5. Am Rev Respir Dis 1993; 147: 540–547.
227. Terada N, Konno A, Tada H, Shirotor K, Ishikawa K, Togawa K. The effect of recombinant human IL-5 on eosinophil accumulation and degranulation in human nasal mucosa. J Allergy Clin Immunol; 1991; 90: 160–168.
228. May GR, Crook P, Moore PK, Page CP. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol 1991; 102: 759–763.
229. Fu Y, Blankenhorn EP. Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains. J Immunol 1992; 148: 2217–2222.
230. Masini E, Di Bello MG, Pistelli A, et al. Generation of nitric oxide from nitrovasodilators modulates the release of histamine from mast cells. J Physiol Pharmacol 1994; 45: 41–53.
231. Barnes ST. Neural mechanisms in asthma. Br Med Bull 1992; 48: 149–168.
232. Griffith T, Randall M. Nitric oxide comes of age. Lancet 1989; I: 875–876.
233. Latinen A, Partanen M, Hervonen A, Peto-Huikko M, Laitinen LA. VIP-like immunoreactive nerves in human respiratory tract. Light and electronmicroscopic study. Histochemistry 1985; 82: 313–319.
234. Golden JA, Nadel JA, Boushey HA. Bronchial hyperirritability in healthy subjects after exposure to ozone. Am Rev Respir Dis 1978; 118: 287–294.
235. Garrelds IM, van Amsterdam JGC, de Graff-In’t Veld C, Gerth van Wijk R, Zijlstra FJ. Nitric oxide metabolites in nasal lavage fluid of patients with house dust mite allergy. Thorax 1995; 50: 275–279.
236. Bousquet J, Dhivert H, Michel FB. Current trends in the management of allergic diseases. Allergy; 49: 31–36.
237. Kobayashi RH, Kietchel III F, Kobayashi AD, Mellion MB. Topical nasal sprays: treatment of allergic rhinitis. Am Fam Physician 1994; 50: 151–157.
238. Noble AL, Forbes RC, Woodbridge HB. Allergic rhinitis. Am Fam Physician 995; 51: 837–846.